Invesco
AMLX icon

Invesco’s Amylyx Pharmaceuticals AMLX Stock Holding History

Invesco’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Sell
139,942
-31,678
-18% -$490K ﹤0.01% 2482
2026
Q1 		$2.39M Sell
171,620
-4,294
-2% -$60.4K ﹤0.01% 2465
2025
Q4 		$2.13M Sell
175,914
-634,726
-78% -$8.62M ﹤0.01% 2589
2025
Q3 		$11M Buy
810,640
+223,757
+38% +$2.11M ﹤0.01% 1769
2025
Q2 		$3.76M Buy
586,883
+541,189
+1,184% +$2.63M ﹤0.01% 2326
2025
Q1 		$162K Buy
+45,694
New +$163K ﹤0.01% 3556
2024
Q2 		– Sell
-24,349
Closed -$69.2K – 3875
2024
Q1 		$69.2K Buy
24,349
+454
+2% +$5.94K ﹤0.01% 3777
2023
Q4 		$352K Sell
23,895
-5,940
-20% -$91K ﹤0.01% 3381
2023
Q3 		$546K Buy
29,835
+3,095
+12% +$65.4K ﹤0.01% 3156
2023
Q2 		$577K Buy
26,740
+3,803
+17% +$103K ﹤0.01% 3161
2023
Q1 		$673K Sell
22,937
-192,533
-89% -$6.69M ﹤0.01% 3115
2022
Q4 		$7.96M Sell
215,470
-46,066
-18% -$1.63M ﹤0.01% 1998
2022
Q3 		$7.36M Buy
+261,536
New +$6.52M ﹤0.01% 1991

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Invesco's AMLX Position: Q2 2026 in Review

Invesco reduced its Amylyx Pharmaceuticals (AMLX) stake by 18% in Q2 2026, selling an estimated $490K and leaving 139,942 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2482.

Invesco first reported a position in AMLX in Q3 2022 and has held it in 13 quarters since. The position peaked at $11M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Invesco held 139,942 shares of Amylyx Pharmaceuticals worth $2.51M as of Q2 2026.
  • Invesco sold 31,678 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $490K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2482 holding.
  • Invesco first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Invesco's Amylyx Pharmaceuticals position peaked at $11M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.